State of the Neoadjuvant Therapy for Glioblastoma Multiforme

State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand? Publisher

Nabian N^{1, 2} ; Ghalehtaki R^{1, 2} ; Zeinalizadeh M³ ; Balana C⁴ ; Jablonska PA⁵

Show Affiliations

1. Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran
4. B.ARGO (Badalona Applied Research Group of Oncology), Medical Oncology Department, Catalan Institute of Oncology Badalona, Badalona, Spain
5. Radiation Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain

Source: Neuro-Oncology Advances Published:2024

Abstract

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite several investigations in this field, maximal safe resection followed by chemoradiotherapy and adjuvant temozolomide with or without tumor-treating fields remains the standard of care with poor survival outcomes. Many endeavors have failed to make a dramatic change in the outcomes of GBM patients.This study aimed to review the available strategies for newly diagnosed GBM in the neoadjuvant setting, which have been mainly neglected in contrast to other solid tumors. © The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Related Docs

View other Related Docs

1. Postoperative Neoadjuvant Temozolomide Followed by Chemoradiotherapy Versus Upfront Chemoradiotherapy for Glioblastoma Multiforme (Neotem) Trial: Interim Results, Neuro-Oncology Advances (2024)

2. A Viral Attack on Brain Tumors: The Potential of Oncolytic Virus Therapy, Journal of NeuroVirology (2024)

3. Lipidomics-Driven Drug Discovery and Delivery Strategies in Glioblastoma, Biochimica et Biophysica Acta - Molecular Basis of Disease (2025)

4. Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence, Journal of Personalized Medicine (2024)

5. Tumor Immunology, Clinical Immunology (2022)

6. Descriptive Epidemiology of Brain and Central Nervous System Tumours: Results From Iran National Cancer Registry, 2010-2014, Journal of Cancer Epidemiology (2020)

7. Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review, Brain Sciences (2023)

8. Is Add-On Bevacizumab Therapy to Temozolomide and Radiotherapy Associated With Clinical Utility for Newly Diagnosed Glioblastoma? a Systematic Review and Meta-Analysis, Neurosurgical Review (2024)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (3)

Mostafa Farzin (1)

Style	Citing Format
MLA	Nabian N, et al.. "State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?." Neuro-Oncology Advances, vol. 6, no. 1, 2024, pp. -.
APA	Nabian N, Ghalehtaki R, Zeinalizadeh M, Balana C, Jablonska PA (2024). State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?. Neuro-Oncology Advances, 6(1), -.
Chicago	Nabian N, Ghalehtaki R, Zeinalizadeh M, Balana C, Jablonska PA. "State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?." Neuro-Oncology Advances 6, no. 1 (2024): -.
Harvard	Nabian N et al. (2024) 'State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?', Neuro-Oncology Advances, 6(1), pp. -.
Vancouver	Nabian N, Ghalehtaki R, Zeinalizadeh M, Balana C, Jablonska PA. State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?. Neuro-Oncology Advances. 2024;6(1):-.
BibTex	@article{ author = {Nabian N and Ghalehtaki R and Zeinalizadeh M and Balana C and Jablonska PA}, title = {State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?}, journal = {Neuro-Oncology Advances}, volume = {6}, number = {1}, pages = {-}, year = {2024} }
RIS	TY - JOUR AU - Nabian N AU - Ghalehtaki R AU - Zeinalizadeh M AU - Balana C AU - Jablonska PA TI - State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand? JO - Neuro-Oncology Advances VL - 6 IS - 1 SP - EP - PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract